

Anti-Alkaline phosphatase [AP-7/6/7]

Catalogue number: 151336

Sub-type: Primary antibody

Images:

Contributor

Inventor: Jacqueline Cordell

Institute: University of Oxford

Images:

Tool details

***FOR RESEARCH USE ONLY**

Name: Anti-Alkaline phosphatase [AP-7/6/7]

Alternate name:

Class: Monoclonal

Conjugate: Unconjugated

Description: Alkaline phosphatases are phosphodiesterases which remove phosphate groups from the 5' end of DNA, RNA and proteins at high pH. The placental-specific isozyme of Alkaline Phosphatase (PLAP) is found in trophoblast cells of normal human mature placenta, seminomas of testis and ovarian carcinomas. Detection of alkaline phosphatase in serum is a marker for ovarian and testicular cancer.

Purpose:

Parental cell:

Organism:

Tissue:

Model:

Gender:

Isotype: IgG1

Reactivity: Bovine

Selectivity:

Host: Mouse

Immunogen: Calf intestinal alkaline phosphatase

Immunogen UNIPROT ID:

Sequence:

Growth properties:

Production details:

Formulation:

Recommended controls:

Bacterial resistance:

Selectable markers:

Additional notes:

Target details

Target: Alkaline phosphatase

Target alternate names:

Target background: Alkaline phosphatases are phosphodiesterases which remove phosphate groups from the 5' end of DNA, RNA and proteins at high pH. The placental-specific isozyme of Alkaline Phosphatase (PLAP) is found in trophoblast cells of normal human mature placenta, seminomas of testis and ovarian carcinomas. Detection of alkaline phosphatase in serum is a marker for ovarian and testicular cancer.

Molecular weight:

Ic50:

Applications

Application: IHC ; IF

Application notes:

Handling

Format: Liquid

Concentration: 1 mg/ml

Passage number:

Growth medium:

Temperature:

Atmosphere:

Volume:

Storage medium:

Storage buffer: PBS with 0.02% azide

Storage conditions: -80° C

Shipping conditions: Shipping at 4° C

Related tools

Related tools:

References

References: DiJoseph et al. 2006. Clin Cancer Res. 12(1):242-9. PMID: 16397048. ; Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. ; Shen et al. 1988. Int J Cancer. 42(5):792-7. PMID: 3263328. ; Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas. ; Bofill et al. 1985. J Immunol. 134(3):1531-8. PMID: 3871452. ; Campana et al. 1985. J Immunol. 134(3):1524-30. PMID: 3918103. ; Human B cell development. II. Subpopulations in the human fetus. ; Human B cell development. I. Phenotypic differences of B lymphocytes in the bone marrow and peripheral lymphoid tissue.

CancerTools.org